

#FutureFresenius: Simplification and focus drives sustained performance

Delivering continued momentum in Q3/24; upgrading FY/24 outlook

Roadshow Copenhagen, 29 November 2024

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.



Financial review Q3/24 02

#FutureFresenius 03


Attachments 04



Business update

Q3/24 **Continued momentum and sustained performance** Further deleveraging based on excellent cash flow; leverage target ratio under review Strong top-line: 9% organic revenue growth Ongoing momentum at Biopharma: Delivering positive EBIT in Q3/24 Structural productivity target for FY/24 already achieved YTD $\overline{\mathbb{M}}$ Strong bottom-line traction: High single-digit EBIT and EPS growth in Q3/24 **#Future Outlook upgraded** Fresenius Before special items; at constant currency


Q3/24 Kabi and Helios above structural growth band



Before special items $^1\,{\rm Organic}$ growth rate adjusted for accounting effects related to Argentina hyperinflation




Kabi: Growth Vector momentum continues






Biopharma: Strong focus on market penetration reflected in recent successes





Tyenne: Strong momentum building





Helios delivering consistent strong organic growth

Helios Germany

O3/24 Revenue

€1,940m

+8%

yoy¹

Helios Spain

Q3/24 Revenue €1,142m


+8%

- Key parameter for 2025 DRG inflator set at 4.41%
- Antibody-drug conjugates: New era of targeted breast cancer therapy
- Dedicated Helios performance programme underway to drive further operational excellence and act against ended energy relief funding

- Start of construction of new hospital in Badajoz
- Quirónsalud patient portal exceeds
 7 million users incorporating one
 million new users in less than a year
- La Luz University Hospital becoming one of only five hospitals in Spain accredited as an Academic Medical Center

¹ Organic growth

Strong revenue growth...



Growth rates adjusted for Argentina hyperinflation

...drives significant bottom-line progress



¹ Before special items; at constant currency

² Growth rate adjusted for Argentina hyperinflation; Before special items; Net income excluding FMC attributable to shareholders of Fresenius SE & Co. KGaA

FFresenius

Æ

Business update 01

Financial review Q3/24 02


#FutureFresenius

03

Attachments 04

02 Financial review Q3/24


Q3/24 **Consistent strong financial performance**





Fresenius Kabi Growth Vectors showing continued momentum

Quarterly financials



Before special items; ¹ Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

Main developments

Strong organic revenue growth of 11%¹ above top-end of structural growth band; pricing effects in Argentina continue to support growth

Growth Vectors with dynamic 16%¹ organic revenue growth (MedTech: 7%¹; Nutrition: 11%¹; Biopharma: 66%¹)

Pharma with good 6%¹ organic revenue growth driven by a strong performance in Europe, International and US compensating softer development in China


Very strong EBIT margin at 15.9% in Q3/24:

- Strong volume growth, favorable product mix and pricing as well as improved structural productivity driving significant margin expansion (+160 bps) and 16% cc growth rate
- Growth Vectors posting 470 bps margin expansion to 14.5%, again within structural margin band; broad based positive development with Biopharma standing out



Fresenius Helios Ongoing strong organic growth performance

Quarterly financials



Main developments

Strong 8% organic revenue growth above top-end of structural growth band driven equally by Helios Germany (8% organic growth) and Helios Spain (8% organic growth):

- Organic growth at Helios Germany was supported by favorable technical reclassifications
- Helios Spain with an ongoing strong admission and price development YoY

Solid 6% YoY EBIT growth supported by strong topline growth

Q3 EBIT and margin seasonally soft driven by Spain

Helios Germany with good EBIT margin of 8.8% helped by energy relief funding

Helios Spain with soft EBIT margin of 6.4% in Q3/24 driven by the usual summer effect and phasing; YTD EBIT margin at Helios Spain strong at 11.2%

Before special items



Cost and productivity savings target achieved ahead of plan



Cost savings ambition for FY/25 already achieved in Q3/24:


- Leaner organization based on excellence measures
- Majority realized by Kabi
- Helios to step-up with dedicated programme as outlined

Operational excellence is key: Structural productivity initiatives to improve cost base sustainably


Incremental structural productivity initiatives expected for FY/25

Historic numbers include Vamed; Targets for FY/24 and FY/25 are now excluding Vamed, but remain unchanged

Disciplined execution unlocking significant cash flow




CAPEX €m



Excellent OCF performance driven by both Kabi and Helios

 Strong contribution from successfully implemented
 Working Capital measures



Free cash flow² €m



FCF improved significantly

Supported by legally required suspension of dividend payments

 CCR (LTM) of 1.2 in Q3/24 – at the upper end of the F³ ambition range (around 1)

Cash flow from continuing operations ¹ % of revenue | ² After acquisitions, dividends and lease liabilities

← → B	usiness update

Simplification and focus drives structurally stronger balance sheet and returns



¹ Prior-year figures have been adjusted due to the deconsolidation of Fresenius Medical Care operations

² At average exchange rates for both net debt and EBITDA; before special items; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend

FY/24 Outlook upgraded based on excellent first nine months

PREVIOUS OUTLOOK

NEW OUTLOOK

Revenue growth (organic):

4–7% growth



Revenue growth (organic): 6-8% growth

Q1-3/24: 8%

Q1-3/24: 11%

EBIT growth (cc): 6–10% growth



Before special items Please refer to slide 26 for a reconciliation of the FY/2023 guidance base

FFresenius

01 Business update

02 Financial review Q3/24

#FutureFresenius

12 Attachments

#FutureFresenius





Growth momentum: High single-digit organic revenue growth in Q1-3/24



Revigoration of EPS momentum: High single-digit growth in Q1-3/24



Structural productivity: 2025 savings target already achieved in Q3/24



Structurally strengthened balance sheet: Accelerated deleveraging



Improved returns: ROIC reached structural ambition range



Cultural change: Driving people strategy across broader leadership team

#FutureFresenius: Rigorous execution drives consistent delivery

F Fresenius

Attachments

#FutureFresenius: Heading towards Re-Juvenation



Simplification + Focus + Performance = VALUE

FFresenius

Business update 01

Financial review Q3/24

#FutureFresenius 03

Attachments 04



Attachments

Outlook for FY/24

	FY/23 base ¹	FY/24 outlook	F Fresenius
Fresenius Kabi	€8,009m €1,145m	 Mid to high single-digit organic revenue growth Q1-3/24: 10% Between 15–16% EBIT margin; structural EBIT margin band of 14–17% Q1-3/24: 15.6% 	Revenue growth (organic): 6-8% growth FY/23 base: €20,307m ¹ Q1-3/24: 8%
Fresenius Helios	€11,952m €1,190m	 Mid single-digit organic revenue growth Q1-3/24: 6% EBIT margin of 10–11% 	<pre> EBIT growth (cc):</pre>
		Q1-3/24: 10.0%	

 $^{1}\,\mbox{Please}$ refer to slide 26 for a reconciliation of the FY/2023 guidance base

Other financial KPIs

€m		FY/23	FY/24 expectation
Drofitzbility	Interest expense	€418m	Upper end of €420 to €440m range
Profitability	Tax rate	28.3%	Between 25 to 26%
	CAPEX % of revenue	5.1%	Below 5% (Previously: around 5%)
Capital	CCR LTM	1.0	Around 1
Capital Allocation	ROIC	5.2%	Above 6% (Previously: around 6%)
	Leverage ratio	3.76x	Lower end of target range of 3.0 to 3.5x net debt/EBITDA (Previously: Within target range of 3.0 to 3.5x net debt/EBITDA)

Guidance base

€m		FY/23 Actual	Portfolio Adjustments Helios	Vamed Exit	Base for Guidance FY/24
	Revenue	8,009			8,009
КАВІ	EBIT	1,145			1,145
FRESENIUS	Revenue	12,320	-368		11,952
HELIOS	EBIT	1,232	-42		1,190
FRESENIUS	Revenue	2,356		-2,356	0
VAMED	EBIT	-16		+16	0
Correcto	Revenue	-386		+732	346
Corporate	EBIT	-99		+30	-69
==	Revenue	22,299	-368	-1,624	20,307
F Fresenius	EBIT	2,262	-42	+46	2,266

Before special items

Attractive biosimilar portfolio and pipeline focused on oncology and autoimmune diseases



Q3/24 & Q1-3/24 Fresenius Kabi Organic Revenue Growth by Product Group

€m	Q3/24	Δ YoY organic ²	Q1-3/24	Δ YoY organic ²
MedTech	384	7%	1,144	6%
Nutrition	597	11%	1,785	11%
Biopharma	177	66%	466	91%
Growth Vectors ¹	1,158	16%	3,396	16%
Pharma (IV Drugs & Fluids)	957	6%	2,870	4%
Corporate	0		0	
Total revenue	2,114	11%	6,266	10%

¹ Consists of MedTech, Nutrition, Biopharma

² Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

Q3/24 & Q1-3/24 Fresenius Kabi EBIT(DA) development

€m	Q3/24	Δ YoY cc ²	Q1-3/24	Δ YoY cc ²	
Total EBITDA	460	14%	1,372	14%	
Margin	21.8%	+170 bps	21.9%	+180 bps	
Total EBIT	335	16%	979	14%	
Margin	15.9%	+160 bps	15.6%	+120 bps	
Growth Vectors ¹	168	53%	462	39%	
Margin	14.5%	+470 bps	13.6%	+450 bps	
Pharma	182	-8%	573	-4%	
(IV Drugs & Fluids) Margin	19.0%	-230 bps	20.0%	-130 bps	
Corporate	-15	-	-56	-	

All figures before special items

- Margin growth at actual rates
- ¹ Consists of MedTech, Nutrition, Biopharma
- ² Growth rate adjusted for Argentina hyperinflation

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/financial-results.

Q3/24 & Q1-3/24 Fresenius Helios **Key Financials**

€m	Q3/24	Δ ΥοΥ cc	Q1-3/24	Δ ΥοΥ ϲϲ
Total revenue	3,082	8% ¹	9,466	6% ¹
Thereof Helios Germany	1,940	8%1	5,725	5% ¹
Thereof Helios Spain	1,142	8%1	3,741	9%1
Total EBIT Margin	244 7.9%	6% -10 bps	949 10.0%	13% +60 bps
Thereof Helios Germany Margin	170 8.8%	8% +10 bps	532 9.3%	14% +80 bps
Thereof Helios Spain Margin	73 6.4%	0% -70 bps	418 11.2%	9% +0 bps
Thereof Corporate	1		-1	

Fresenius Helios: Key Metrics

	Q1-3/24	FY/23	ΔΥοΥ
Helios Germany			
Hospitals	85	86	-1%
- Acute care hospitals	82	83	-1%
Beds	30,011	29,976	0%
- Acute care hospitals	29,445	29,410	0%
Admissions	4,161,348	5,470,871	0%
 patients treated in hospital 	866,294	1,136,446	1%
- patients treated as outpatient	3,295,054	4,334,425	0%
Helios Spain (incl. Latin America)			
Hospitals	57	59	-3%
Beds	8,132	8,299	-2%
Admissions (including outpatients)	15,353,414	20,301,158	2%
 patients treated in hospital 	864,807	1,153,240	1%
 patients treated as outpatient 	14,488,607	19,147,918	2%

Q1-3/24 Fresenius Group Calculation of Noncontrolling Interests

€m	Q1-3/24	Q1-3/23
Earnings before tax and noncontrolling interests	1,507	1,373
Taxes	-378	-325
Noncontrolling interests, thereof	-58	-54
Fresenius Kabi	-49	-47
Fresenius Helios	-8	-4
Corporate	-1	-3
Net income from deconsolidated operations	205	160
Net income attributable to Fresenius SE & Co. KGaA	1,276	1,154

Before special items For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <u>https://www.fresenius.com/results-center</u>.

Q3/24 & Q3/24 LTM Fresenius Group Cash flow development

€m	Q3/24	Q3/23	Q3/24 LTM	Q3/23 LTM
OCF	763	603	2,719	2,015
thereof Kabi	374	380	1,224	879
thereof Helios	454	208	1,808	1,333
% OCF Margin	14.4%	12.1%	12.8%	10.0%
Capex (net)	-231	-257	-942	-1,102
<i>Capex in % of revenue</i>	-4.4%	-5.2%	-4.4%	-5.5%
Dividends received from FMC	-	-	112	106
Acquisitions (net)	133	-181	296	-235
Dividends paid	-	1	-7	-551
Lease liabilities	-42	-64	-175	-188
FCF	623	102	2,003	45

Cash flow from continuing operations

Fresenius Roadshow Copenhagen, 29 November 2024 © Fresenius SE & Co. KGaA Investor Relations

Q3/24 & Q1-3/24 Fresenius Group Reconciliation adjusted Free Cash Flow for CCR

€m	Q3/24	Q3/23	Q1-3/24	Q1-3/23
Operating Cash Flow	763	603	1,444	802
Capex (net)	-231	-257	-568	-652
Free Cash Flow (before acquisitions, dividends, and lease liabilities)	532	346	876	-150
Special items (net income before minorities)	+31	+35	+62	+86
Interests (before special items)	+116	+102	+336	+285
Taxes (before special items)	+107	+94	+378	+325
Adjusted Free Cash Flow for CCR	786	577	1,652	846

Cash flow from continuing operations

Q3/24 Cash Flow development

	Operating Cash Flow				Capex (net) ¹			Free Cash Flow ²				
€m	Q3/24	Q3/23	Q3/24 Margin	Q3/23 Margin	Q3/24	Q3/23	Q3/24 % rev.	Q3/23 % rev.	Q3/24	Q3/23	Q3/24 Margin	Q3/23 Margin
FRESENIUS KABI	374	380	17.7%	18.8%	-71	-110	-3.4%	-5.4%	303	270	14.3%	13.4%
FRESENIUS HELIOS	454	208	14.7%	7.3%	-152	-143	-4.9%	-5.0%	302	65	9.8%	2.3%
Corporate/Other	-65	15			-8	-4			-73	11		
F Fresenius	763	603	14.4%	12.1%	-231	-257	-4.4%	-5.1%	532	346	10.0%	7.0%

Cash flow from continued operations ¹ Total incl. FME dividend ² Before acquisitions, dividends and lease liabilities

Fresenius Roadshow Copenhagen, 29 November 2024 © Fresenius SE & Co. KGaA Investor Relations

Q3/24 LTM Cash Flow development

	Operating Cash Flow				Capex (net) ¹				Free Cash Flow ²			
€m	Q3/24 LTM	Q3/23 LTM	Q3/24 LTM Margin	Q3/23 LTM Margin	Q3/24 LTM	Q3/23 LTM	Q3/24 LTM % rev.	Q3/23 LTM % rev.	Q3/24 LTM	Q3/23 LTM	Q3/24 LTM Margin	Q3/23 LTM Margin
	1,224	879	14.8%	10.9%	-370	-472	-4.5%	-5.8%	854	407	10.3%	5.1%
FRESENIUS HELIOS	1,808	1,333	14.4%	11.3%	-537	-590	-4.3%	-5.0%	1,271	743	10.1%	6.3%
Corporate/Other	-313	-197			77	66			-236	-131		
F Fresenius	2,719	2,015	12.8%	10.0%	-830	-996	-3.9%	-5.0%	1,889	1,019	8.9%	5.0%

Cash flow from continued operations ¹ Total incl. FME dividend ² Before acquisitions, dividends and lease liabilities

Fresenius Roadshow Copenhagen, 29 November 2024 © Fresenius SE & Co. KGaA Investor Relations

Q3/24 Revenue by Business Segment – FX, Acquisitions/Divestitures

€m	Q3/24	Q3/23	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth ¹	Acquisi- tions	Divestiture/ Others
Fresenius Kabi	2,114	2,021	5%	-5%	10%	11%	0%	-1%
Fresenius Helios	3,082	2,863	8%	0%	8%	8%	0%	0%
Corporate/ Other	107	83	n/a	n/a	n/a	n/a	n/a	n/a
Total	5,303	4,967	7%	-2%	9%	9%	0%	0%

¹ Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

Q1-3/24 **Revenue by Business Segment – FX, Acquisitions/Divestitures**

€m	Q1-3/24	Q1-3/23	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth ¹	Acquisi- tions	Divestiture/ Others
Fresenius Kabi	6,266	6,013	4%	-6%	10%	10%	0%	0%
Fresenius Helios	9,466	8,860	7%	1%	6%	6%	0%	0%
Corporate/ Other	268	258	n/a	n/a	n/a	n/a	n/a	n/a
Total	16,000	15,131	6%	-2%	8%	8%	0%	0%

¹ Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

Financial Calendar / Contact

Financial Calendar

Please note that these dates could be subject to change.

26 Feb 2025 Results FY/24 07 May 2025 Results Q1/25 23 May 2025 Annual General Meeting 06 Aug 2025 Results Q2/25 05 Nov 2025 Results Q3/25

Events

Please note that these dates could be subject to change.

	, , , , , , , , , , , , , , , , , , ,
07 Nov 2024	Roadshow London/UK
14 Nov 2024	HSBC Luxembourg Day
19 Nov 2024	DZ Bank Equity Conference, Frankfurt/Germany
19 Nov 2024	Roadshow Tokyo/Japan
20 Nov 2024	Roadshow Hong Kong
21 Nov 2024	Roadshow Singapore
28 Nov 2024	Roadshow Stockholm/Sweden
29 Nov 2024	Roadshow Copenhagen/Denmark
04 Dec 2024	Berenberg European Conference, Pennyhill/UK
13 Jan 2025	J.P. Morgan Healthcare Conference, San Francisco/USA
21 Jan 2025	KeplerCheuvreux German Corporate Conference, Frankfurt/Germany

Social Media

Follow Fresenius Investor Relations on LinkedIn:



For further information and current news: www.fresenius.com

lin

www.linkedin.com/company/fresenius-investor-relations

www.twitter.com/fresenius ir

Contact

Investor Relations Fresenius SE & Co, KGaA phone: +49 6172 608-97033 e-mail: ir-fre@fresenius.com



#FutureFresenius

November 2024